A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

NCT03320707 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Daratumumab
DRUG: Placebo
DRUG: rHuPH20

Sponsor

Janssen Research & Development, LLC